Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;33(6):e14204.
doi: 10.1111/jsr.14204. Epub 2024 Apr 8.

Alpha-synuclein pathology in isolated rapid eye movement sleep behaviour disorder: a meta-analysis

Imran H Iftikhar  1   2 , Sohaila AlShimemeri  3 , Hussein Rabah  1 , Saad Tauheed Rao  4 , Ahmed S BaHammam  5   6
Affiliations
Review

Alpha-synuclein pathology in isolated rapid eye movement sleep behaviour disorder: a meta-analysis

Imran H Iftikhar et al. J Sleep Res. 2024 Dec.

Abstract

Accumulating evidence indicates that patients with isolated rapid eye movement sleep behaviour disorder (iRBD), a prodromal stage of synucleinopathies, show abnormal deposition of misfolded alpha-synuclein (a-Syn) in peripheral tissues. The clinical utility of testing for a-Syn in iRBD is unclear. This meta-analysis focused on the utility of testing for the abnormal a-Syn phosphorylated at Ser129 (p-syn) and a-Syn seeding activity (a-Syn seed amplification assays [aSyn-SAA]). Following an electronic database search, 15 studies were included that provided at a minimum data on test positivity in participants with iRBD. Test positivity from cerebrospinal fluid (CSF) was 80% (95% confidence interval [CI] 68-88%, I2 = 71%) and for skin was 74.8% (95% CI 53.2-88.5%, I2 = 64%) for aSyn-SAA and 78.5% (95% CI 70.4-84.9%, I2 = 14%) for p-syn. The phenoconversion rate ratio of biopsy-positive versus biopsy-negative iRBD was 1.28 (95% CI 0.68-2.41, I2 = 0%). Skin as a source had a specificity of 99% (95% CI 95-100%, I2 = 0%; p = 0.01 compared to CSF). As a test, p-syn, had a specificity of 100% (95% CI 93-100%, I2 = 0%; p < 0.001) compared to aSyn-SAA. The odds ratio of a-Syn test positivity in iRBD versus other RBDs was 112 (95% CI 20-629, I2 = 0%). These results demonstrate clinically significant test positivity in iRBD and favour skin over CSF as the source of a-Syn pathological analysis, and p-syn over aSyn-SAA as the testing method. Overall, these findings indicate that testing for a-Syn could help in differentiating iRBD from RBD secondary to other conditions.

Keywords: alpha‐synuclein seed amplification assay; alpha‐synucleinopathy; cerebrospinal fluid; meta‐analysis; phenoconversion; rapid eye movment sleep behaviour disorder.

PubMed Disclaimer

References

REFERENCES

    1. Al‐Qassabi, A., Tsao, T. S., Racolta, A., Kremer, T., Cañamero, M., Belousov, A., Santana, M. A., Beck, R. C., Zhang, H., Meridew, J., & Pugh, J. (2021). Immunohistochemical detection of Synuclein pathology in skin in idiopathic rapid eye movement sleep behavior disorder and parkinsonism. Movement Disorders, 36, 895–904.
    1. Antelmi, E., Donadio, V., Incensi, A., Plazzi, G., & Liguori, R. (2017). Skin nerve phosphorylated alpha‐synuclein deposits in idiopathic REM sleep behavior disorder. Neurology, 88, 2128–2131.
    1. Antelmi, E., Pizza, F., Donadio, V., Filardi, M., Sosero, Y. L., Incensi, A., Vandi, S., Moresco, M., Ferri, R., Marelli, S., Ferini‐Strambi, L., Liguori, R., & Plazzi, G. (2019). Biomarkers for REM sleep behavior disorder in idiopathic and narcoleptic patients. Annals of Clinical Translational Neurology, 6, 1872–1876.
    1. Arotcarena, M. L., Dovero, S., Prigent, A., Bourdenx, M., Camus, S., Porras, G., Thiolat, M. L., Tasselli, M., Aubert, P., Kruse, N., Mollenhauer, B., Trigo Damas, I., Estrada, C., Garcia‐Carrillo, N., Vaikath, N. N., el‐Agnaf, O. M. A., Herrero, M. T., Vila, M., Obeso, J. A., … Bezard, E. (2020). Bidirectional gut‐to‐brain and brain‐to‐gut propagation of synucleinopathy in non‐human primates. Brain, 143, 1462–1475.
    1. Bacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser, M., Eninger, T., Lambert, M., Pilotto, A., Shimshek, D. R., Neumann, U., Kahle, P. J., Staufenbiel, M., Neumann, M., Maetzler, W., Kuhle, J., & Jucker, M. (2016). Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron, 91, 494–496.

MeSH terms

Substances

LinkOut - more resources